Categories Earnings, Health Care
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second quarter of 2024.
- Second-quarter revenue increased 5% from last year to $7.0 billion, aided by higher product sales in HIV, Liver Disease, and Oncology
- Earnings, on a per-share basis, were $1.29 in the second quarter, compared to $0.83 in the same period in 2023
- Adjusted earnings per share increased to $2.01 in the June quarter from $1.34 in the prior-year period
- Net income attributable to Gilead advanced to $1.61 billion in Q2 from $1.05 billion in the year-ago quarter
- As of June 30, 2024, the company had $2.8 billion of cash, cash equivalents, and marketable debt securities, vs. $8.4 billion a year earlier
- During the quarter, Gilead generated $1.3 billion in operating cash flow; it paid dividends of $972 million and repurchased $100 million of common stock
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a positive year, what 2025 holds for IBM?
International Business Machines Corporation (NYSE: IBM) has delivered impressive financial performance in 2024 by focusing on higher-value businesses. The company’s software business experienced stable growth, offsetting softness in its consulting
What to expect when Delta Air Lines (DAL) reports Q4 2024 earnings
Shares of Delta Air Lines (NYSE: DAL) fell 2% on Friday. The stock has gained 17% over the past three months. The airline is scheduled to report its earnings results
Walgreens Boots Alliance expected to report mixed Q1 2025 results
For Walgreens Boots Alliance, Inc. (NASDAQ: WBA), 2024 was a challenging year as it lost market share to competitors and closed several stores amid persistent operational headwinds. It is expected
